Status:

COMPLETED

Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy

Lead Sponsor:

University of California, San Francisco

Collaborating Sponsors:

United States Department of Defense

Conditions:

Prostate Cancer

Eligibility:

MALE

Brief Summary

This is a phase I study to evaluate the feasibility and safety of using MRI/MRS to identify the dominant intraprostatic lesion (DIL) and to selectively boost the lesion using inverse planned high dose...

Detailed Description

1.1 The goal of radiotherapy is to deliver a high dose of radiation to the target volume while minimizing the dose to the surrounding normal tissue. Using CT based three-dimensional treatment planning...

Eligibility Criteria

Inclusion

  • Patient must be a candidate for HDR prostate brachytherapy
  • Patient must be able to have MR scan
  • Patient must have a visible DIL on MRS
  • Patient has signed the protocol consent form
  • No prior pelvic or prostate radiation or chemotherapy for any reason
  • Induction hormonal therapy beginning ≤ 120 days prior to study entry is acceptable only if there is a MRI/MRS done prior to starting hormonal therapy
  • Prostate specific antigen prior to any (hormonal) therapy must be ≤ 20 ng/ml
  • One of the following combinations of factors:
  • Clinical stage T2a-2b, Gleason score 2-6 and PSA ≥ 10 but ≤ 20
  • Clinical stage T3a-T3b, Gleason score 2-6 and PSA ≤ 20
  • Clinical stage T2a-T3b, Gleason score 7-10 and PSA ≤ 20

Exclusion

  • Patient with hip prosthesis
  • Patient with pacemaker
  • Patient with history of radical surgery for prostate
  • Patient with claustrophobia
  • Patient with metal in body not safe for MR
  • Stage T4 disease
  • Lymph node involvement (N1)
  • Evidence of distant metastases (M1)
  • Previous hormonal therapy beginning \> 120 days prior to registration
  • Hormonal therapy prior to MRI/MRS

Key Trial Info

Start Date :

March 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2012

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT00807820

Start Date

March 1 2008

End Date

January 1 2012

Last Update

January 24 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California, San Francisco

San Francisco, California, United States, 94143-1708